PMID- 29664423
OWN - NLM
STAT- MEDLINE
DCOM- 20180927
LR  - 20181023
IS  - 1308-4488 (Electronic)
IS  - 1016-5169 (Linking)
VI  - 46
IP  - 3
DP  - 2018 Apr
TI  - Long-term follow-up of antithrombotic management patterns in acute coronary 
      syndrome patients.
PG  - 175-183
LID - 10.5543/tkda.2017.66724 [doi]
AB  - OBJECTIVE: The aim of this study was to evaluate the longterm, post-discharge 
      follow-up of antithrombotic management patterns (AMPs), clinical outcomes, and 
      real-life health status of patients hospitalized acute coronary syndrome (ACS). 
      METHODS: A total of 1034 patients hospitalized for ACS within 24 hours of symptom 
      onset who survived to discharge were included. Of those, 514 had ST-segment 
      elevation myocardial infarction (STEMI) and 520 had unstable angina 
      (UA)/non-STEMI (NSTEMI). Data on follow-up AMPs, clinical outcomes, and health 
      status were collected during 24 months of follow-up. RESULTS: The overall 
      all-cause mortality was 6.4% (6.7% in UA/NSTEMI and 6.0% in STEMI patients), 
      cardiovascular (CV) events had occurred in 9.4% (9.8% in UA/NSTEMI and 8.9% in 
      STEMI patients), and bleeding events in 2.0% (2.3% in STEMI and 1.7% in UA/NSTEMI 
      patients) of patients at 2 years after discharge. EuroQol-visual analogue scales 
      scores increased from 78.9 to 81.6 in STEMI patients, and from 76.0 to 76.2 in 
      UA/NSTEMI patients. Discharge and 2-year postdischarge scores for the EuroQol-5D 
      index were 0.7 and 0.9, respectively in STEMI patients, while it was 0.8 for each 
      period in UA/STEMI patients. Overall, 57.5% of the patients on dual antiplatelet 
      (AP) therapy at discharge remained on this treatment at 2 years after discharge. 
      The use of 1AP/0 anticoagulant (AC) and >/=2AP/0AC were associated with a CV event 
      risk of 10.5% and 8.9%, a mortality risk of 10.5% and 5.8%, and a bleeding event 
      risk of 0.9% and. 2.2%, respectively. CONCLUSION: These findings in a real-life 
      population of ACS patients emphasize the importance of longer-term follow-up of 
      ACS patients surviving hospitalization and support the likelihood of more 
      favorable long-term outcomes in ACS management with the current treatment 
      practices.
FAU - Ertas, Fatih Sinan
AU  - Ertas FS
AD  - Department of Cardiology, Ankara University Faculty of Medicine, Ankara, Turkey. 
      fs.ertas@gmail.com.
FAU - Tokgozoglu, Lale
AU  - Tokgozoglu L
CN  - EPICOR Study Group
LA  - eng
PT  - Journal Article
PL  - Turkey
TA  - Turk Kardiyol Dern Ars
JT  - Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir
JID - 9426239
RN  - 0 (Anticoagulants)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - *Acute Coronary Syndrome/drug therapy/epidemiology/mortality
MH  - Angina, Unstable/drug therapy/epidemiology/mortality
MH  - Anticoagulants/*therapeutic use
MH  - Aspirin/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Male
MH  - Myocardial Infarction/drug therapy/epidemiology/mortality
MH  - Treatment Outcome
MH  - Turkey/epidemiology
EDAT- 2018/04/18 06:00
MHDA- 2018/09/28 06:00
CRDT- 2018/04/18 06:00
PHST- 2018/04/18 06:00 [entrez]
PHST- 2018/04/18 06:00 [pubmed]
PHST- 2018/09/28 06:00 [medline]
AID - 10.5543/tkda.2017.66724 [doi]
PST - ppublish
SO  - Turk Kardiyol Dern Ars. 2018 Apr;46(3):175-183. doi: 10.5543/tkda.2017.66724.